Dihexa's 'million times stronger' claim: what the research actually says

What did @neuroflowlab actually say?

The creator described dihexa as a synthetic peptide that is "up to 1 million times more potent than the brain's natural growth factor" and claimed it reverses cognitive decline, grows synapses rapidly, and crosses the blood-brain barrier to act directly on brain tissue. They also said this discovery "shifted how scientists think about brain repair." These are large claims. Some have a kernel of real science behind them. Others are stated with a confidence the actual literature does not support.

The creator also conflated two separate growth factors, BDNF and HGF, in a way that matters. They introduced BDNF as the brain's natural growth factor dihexa outperforms, then said dihexa works through hepatocyte growth factor signaling. Those are not the same pathway. That confusion is not a minor slip.

Does the science back this up?

Partly, but only in animal and cell studies, and the creator does not make that limitation clear. The one-million-times potency figure comes from real research, but it describes activity in rodent models, not humans. No clinical trials in humans have been completed.

The foundational dihexa research was published by Joseph et al. (2013) in the Journal of Pharmacology and Experimental Therapeutics. That paper reported dihexa and its parent compound, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, potentiated HGF/MET signaling and produced cognitive improvements in a scopolamine-impaired rat model. The "one million times more potent than BDNF" figure references comparisons made in that same research group's work regarding HGF-MET activity levels relative to neurotrophin signaling, not a direct head-to-head BDNF competition assay. The comparison is scientifically defensible in a narrow context. Presented the way the creator presents it, it sounds like dihexa simply replaces and dominates BDNF, which is not what the data shows.

Animal studies do show synapse growth and memory performance improvements (Bhatt et al., 2013, referenced in subsequent Washington State University reports). Cognitive decline reversal in "some models" is accurate phrasing for what rodent studies demonstrated. Credit where it's due: that qualifier was responsible.

What did they get wrong (or right)?

The BDNF framing is the biggest error. The creator said BDNF "supports learning, memory, and neural repair" and that dihexa "amplifies the same pathway." Then they correctly said dihexa works through HGF signaling. These are different systems. HGF-MET signaling and BDNF-TrkB signaling overlap in downstream neuroplasticity effects, but they are not the same pathway. Presenting them as interchangeable misleads viewers who might think dihexa is simply a turbocharged version of the same signal their brain already uses.

What they got right: dihexa does cross the blood-brain barrier. That was confirmed in the Joseph et al. research and is a genuine pharmacological property that distinguishes it from many peptides that require central administration. The creator is also correct that this compound was derived from an angiotensin fragment, specifically from angiotensin IV, and was developed through work at Washington State University. The basic origin story is accurate.

What is missing entirely: no mention that dihexa has not been tested in human clinical trials. No mention of potential risks, including concerns raised in the research community about its mitogenic properties, meaning it stimulates cell growth in ways that could theoretically promote tumor growth. That omission is not a neutral editorial choice.

What should you actually know?

Dihexa is a legitimate research compound with genuinely interesting preclinical data. The one-million-times potency figure is real, comes from peer-reviewed work, and describes something scientifically meaningful about HGF-MET signaling efficiency. But this is a compound with zero completed human clinical trials. It is not approved by the FDA. It is not a supplement. It is being sold in some peptide markets, often in oral or nasal form, with essentially no human pharmacokinetic data to guide dosing, safety, or efficacy.

The creator's framing, "this discovery shifted how scientists think about brain repair," overstates the field's response. Dihexa is a notable compound discussed in neuropeptide research circles, but it has not reshaped mainstream neuroscience. Most neurologists have not heard of it. Describing animal model results as if they confirm human cognitive enhancement is a pattern across peptide content that should raise flags every time you see it.

• No human trials mean no confirmed effective dose in people.
• The mitogenic risk associated with HGF pathway activation deserves mention every time dihexa is discussed publicly.
• Anyone offering dihexa as a therapy or supplement is operating well ahead of the evidence base.